Published in Hepatitis Weekly, July 4th, 2005
"Gene therapy might be a promising therapeutic approach for advanced hepatocellular carcinoma (HCC) not amenable to any effective traditional treatment. The aim of the study was to evaluate the in vitro and in vivo efficacy of combined gene therapy of HCC with two different MoMLV-derived retroviral vectors, an MFG-and a LXSN-derived vector, both containing herpes simplex virus thymidine kinase (HSV-TK) and human interleukin-2 (hIL-2)," scientists in Italy report.
"In vitro experiments on HCC cells showed efficient killing of transduced cells and efficient bystander effect after...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.